文献速递帕金森病与运动障碍

辛伐他汀作为帕金森病疾病修饰治疗的评价:一项随机临床试验

Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2022-01-01

这项在英格兰23个国民健康服务信托机构进行的双盲、平行组、安慰剂对照的无效性试验,纳入235例中度帕金森病患者,随机分配至辛伐他汀组或安慰剂组。主要结局分析(n=178)显示,24个月时辛伐他汀组在不服药状态下的MDS-UPDRS第三部分评分较安慰剂组额外恶化1.52分(双侧80%CI,-0.77至3.80;单侧无效性检验P=0.006)。结论认为辛伐他汀作为疾病修饰治疗无效,不支持进入3期试验。

要点

  • 辛伐他汀组24个月时MDS-UPDRS III评分较安慰剂组额外恶化1.52分(双侧80%CI -0.77至3.80)。
  • 单侧无效性检验P=0.006,辛伐他汀作为疾病修饰治疗无效。
  • 结论不支持推进至3期试验。

核心结论

  • 在这项随机临床试验中,辛伐他汀对中度帕金森病患者作为疾病修饰治疗无效,未提供支持推进至3期试验的证据。

研究设计与样本

  • 该研究为双盲、平行组、安慰剂对照的无效性随机临床试验,于2016年3月至2020年5月在英格兰23个国民健康服务信托机构进行。
  • 纳入40至90岁、诊断特发性帕金森病、服药时改良Hoehn和Yahr分期≤3.0、且服用多巴胺能药物出现剂末现象的患者。
  • 参与者按1:1计算机生成随机序列分配至辛伐他汀或匹配安慰剂,按中心和Hoehn和Yahr分期分层。
  • 辛伐他汀组先接受1个月辛伐他汀40 mg每日,随后23个月辛伐他汀80 mg每日,之后2个月洗脱期。
  • 共235例参与者被招募,其中97例(41%)为女性,233例(99%)为白人,平均(SD)年龄65.4(9.4)岁;216例进展至80 mg剂量。

主要发现

  • 主要结局分析(n=178)显示,24个月时辛伐他汀组在不服药状态下的MDS-UPDRS第三部分评分较安慰剂组额外恶化1.52分(双侧80%CI,-0.77至3.80;单侧无效性检验P=0.006)。
  • 接受0 mg辛伐他汀的参与者报告37例严重不良事件(包括3例死亡)和171例不良事件;接受40 mg或80 mg辛伐他汀的参与者报告37例严重不良事件和150例不良事件。
  • 4例参与者因不良事件退出试验。

关键数值与推荐

  • 主要结局为24个月时不服药状态下MDS-UPDRS第三部分评分的变化(高分表示结局更差)。
  • 主要无效性分析纳入开始80 mg阶段且具有有效主要结局数据的参与者。
  • 安全性分析纳入所有开始试验治疗的参与者,按事件发生时剂量报告。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current treatments manage symptoms of Parkinson disease (PD), but no known treatment slows disease progression. Preclinical and epidemiological studies support the potential use of statins as disease-modifying therapy. OBJECTIVE: To determine whether simvastatin has potential as a disease-modifying treatment for patients with moderate PD. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, a double-blind, parallel-group, placebo-controlled futility trial, was conducted between March 2016 and May 2020 within 23 National Health Service Trusts in England. Participants aged 40 to 90 years with a diagnosis of idiopathic PD, with a modified Hoehn and Yahr stage of 3.0 or less while taking medication, and taking dopaminergic medication with wearing-off phenomenon were included. Data were analyzed from May 2020 to September 2020, with additional analysis in February 2021. INTERVENTIONS: Participants were allocated 1:1 to simvastatin or matched placebo via a computer-generated random sequence, stratified by site and Hoehn and Yahr stage. In the simvastatin arm, participants entered a 1-month phase of simvastatin, 40 mg daily, followed by 23 months of simvastatin, 80 mg daily, before a 2-month washout period. MAIN OUTCOMES AND MEASURES: The prespecified primary outcome was 24-month change in Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) part III score measured while not taking medication (high scores indicate worse outcome). The primary futility analysis included participants who commenced the 80-mg phase and had valid primary outcome data. The safety analysis included all participants who commenced trial treatment and is reported by dose at time of event. RESULTS: Of 332 patients assessed for eligibility, 32 declined and 65 were ineligible. Of 235 recruited participants, 97 (41%) were female, 233 (99%) were White, and the mean (SD) age was 65.4 (9.4) years. A total of 216 patients progressed to the 80-mg dose. Primary outcome analysis (n = 178) indicated the simvastatin group had an additional deterioration in MDS-UPDRS III score while not taking medication at 24 months compared with the placebo group (1.52 points; 2-sided 80% CI, -0.77 to 3.80; 1-sided futility test P = .006). A total of 37 serious adverse events (AEs), including 3 deaths, and 171 AEs were reported for participants receiving 0-mg simvastatin; 37 serious AEs and 150 AEs were reported for participants taking 40 mg or 80 mg of simvastatin. Four participants withdrew from the trial because of an AE. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, simvastatin was futile as a disease-modifying therapy in patients with PD of moderate severity, providing no evidence to support proceeding to a phase 3 trial. TRIAL REGISTRATION: ISRCTN Identifier: 16108482.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Stevens KN, Creanor S, Jeffery A, et al. Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 36315128. doi:10.1001/jamaneurol.2022.3718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。